References
- Löwenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051–1062.
- Mayer RJ, Davis RB, Schiffer CA, et al Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994;331:896–903.
- Schlenk RF, Benner A, Krauter J, et al Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004;22:3741–3750.
- Seshadri T, Keating A. Is there a role for autotransplants in AML in first remission? Biol Blood Marrow Transplant 2009;15:17–20.
- Burnett AK, Wheatley K, Goldstone AH, et al The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002;118:385–400.
- Koreth J, Schlenk R, Kopecky KJ, et al Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009;301:2349–2361.
- Cornelissen JJ, Putten WLJ, Verdonck LF, et al Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007;109:3658–3666.
- Tallman MS, Rowlings PA, Milone G, et al Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. Blood 2000;96:1254–1258.
- Cahn JY, Labopin M, Sierra J, et al No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Br J Haematol 2000;110:308–314.
- Laane E, Rangert Derolf A, Björklund E, et al The effect of allogeneic stem cell transplantation on outcome in younger acute myeloid leukemia patients with minimal residual disease detected by flow cytometry at the end of post-remission chemotherapy. Haematologica 2006;91:833–836.
- Maurillo L, Buccisano F, Del Principe MI, et al Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008;30:4944–4950.
- Dufoir T, Saux MC, Terraza B, et al Comparative cost of allogeneic or autologous bone marrow transplantation and chemotherapy in patients with acute myeloid leukaemia in first remission. Bone Marrow Transplant 1992;10:323–329.
- Redaelli A, Botteman MF, Stephens JM, Brandt S, Pashos CL. Economic burden of acute myeloid leukemia: a literature review. Cancer Treat Rev 2004;30:237–247.
- Gonen C, Celik I, Cetinkaya YS, et al Cytarabine-induced fever complicating the clinical course or leukemia. Anticancer Drugs 2005;16:59–62.
- Byrd JC, Mrózek K, Dodge RK, et al Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002;100:4325–4336.
- Yanada M, Matsuo K, Emi N, Naoe T. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005;103:1652–1658.